Page 13 - Oncological Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 07, 2021   -Xenter’s Expanding Team of Industry Leaders Poised to Advance Device/Data/Drug Technologies for Interventional Medicine, Pharmaceutical Advancements and Digital Health-   SALT LAKE CITY--(BUSINESS WIRE)-- Xenter, Inc. (XenterMD.com), the world’s first start-up Device-Data-Drug healthcare technologies company, today announced the appointment of four additional industry leaders to its Board of Directors and the closing of a $12M Series A offering of preferred stock. The additional members are Robert S. Langer, an Institute Professor at MIT and the most cited...

 E-Mail New York, NY (May 6, 2021) -- Researchers have finally cracked the code of a bewildering pediatric disease that sets off a characteristic cytokine storm--a harmful immune system overaction resembling one that arises in COVID-19 cases--and can lead to catastrophic multisystem organ failure or neurodegeneration. Their study, which identifies the cause of the cytokine storm and possible treatments, was published in Nature Medicine in May. The mystery of this disease, Langerhans-cell histiocytosis (LCH), runs deep. Its symptoms vary widely, and LCH has the ability to infiltrate almost a...

Vaxalto Biotherapeutics and Mount Sinai Enter into Exclusive License Agreement for the Development and Commercialization of Novel Immunotherapeutic Oncolytic Viruses for Treatment of Cancer USA - English Share this article Share this article NEW YORK, March 3, 2021 /PRNewswire/ -- Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, and Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, have partnered to develop novel...

 E-Mail (New York, NY) February 10, 2021 - A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February. The therapeutic targets could be applicable not just to AML but also to the blood cancer myelodysplastic syndrome a...